Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on January 11, 2021, covering events occurring on January 5, 2021. The filing details the entry into a Material Definitive Agreement regarding intellectual property licensing.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt). Instead, it outlines specific financial terms of a new Patent License Agreement with AIkido Pharma Inc.:
- Upfront Payment: AIkido agreed to pay a one-time cash payment of $500,000.
- Royalties: AIkido will pay royalties equal to 2% of Net Sales in the licensed Field of Use (cancer treatment and symptoms).
- Equity Consideration: AIkido issued 500 shares of Series M Convertible Preferred Stock to the Licensor.
- Stock Terms: Each preferred share has a Stated Value of $1,000 and a Conversion Price of $0.80. For a specific reverse stock split vote, each share carries voting rights equal to 20,000 shares of AIkido common stock.
Material Changes and Strategic Developments
The primary material change is the execution of an exclusive, worldwide, sublicensable, royalty-bearing license granted to AIkido Pharma Inc. The license covers:
- Development and commercialization of products for the treatment of cancer and cancer-related symptoms.
- A potential non-exclusive sublicense to University of Maryland, Baltimore (UMB) patent rights regarding neuroinflammatory diseases in cancer patients, contingent on the Licensor exercising an option under a prior agreement.
Outlook, Risks, and Contingencies
The agreement remains in effect until the expiration or abandonment of all licensed patents, unless terminated earlier. The filing incorporates press releases dated January 6 and January 11, 2021, regarding the execution of the agreement. No specific forward-looking financial guidance or risk factors beyond the standard agreement termination clauses are detailed in this text.
Key Facts for Investor Verification
- Verify the definition of "Net Sales" in the full agreement (Exhibit 10.1) to understand the royalty calculation basis.
- Confirm the status of the Licensor's option to exercise rights under the University of Maryland, Baltimore agreement.
- Review the full terms of the Series M Convertible Preferred Stock, including adjustment mechanisms for the conversion price.
- Assess the impact of the $500,000 cash receipt on the company's immediate liquidity position.